Equity Transactions (Tables)

12 Months Ended

Jun. 30, 2020

Schedule of estimation of estimated the fair value of the warrants granted

For the year ended June 30, 2018, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

Expected life (year)	4
Expected volatility	53.56%  -56.10	%
Expected annual rate of quarterly dividends	0.00	%
Risk-free rate(s)	1.67 - 2.84	%

For the year ended June 30, 2019, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

Expected life (year)	4
Expected volatility	47.46-55.12	%
Expected annual rate of quarterly dividends	0.00	%
Risk-free rate(s)	2.14-2.93	%

For the year ended June 30, 2020, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

Expected life (year)	4
Expected volatility	47.99-90.32	%
Expected annual rate of quarterly dividends	0.00	%
Risk-free rate(s)	0.25-1.63	%

Schedule of proceeds of the Offering

The Company accounted for the proceeds of the Offering at February 27, 2019 as follows:

Gross proceeds	$	2,500,000
Less: Offering costs		150,000
Net proceeds		2,350,000
Portion allocated to derivative liability – warrants		(1,527,259)
Net proceeds from issuance of common stock	$	822,741

The Company accounted for the proceeds of the Offering at January 25, 2020 as follows:

Gross proceeds	$	8,625,000
Less: offering costs		(1,167,425)
Net proceeds from issuance of common stock	$	7,457,575

The Company accounted for the proceeds of the Offering at May 22, 2020 as follows:

Gross proceeds	$	10,220,000
Less: offering costs		(1,000,600)
Net proceeds from issuance of common stock	$	9,219,400

Schedule of projected annual volatility

1 Year
2/27/2019	75	%
6/30/2019	76.1	%

Series B Convertible Debentures [Member]

Schedule of estimation of estimated the fair value of the warrants granted

For the year ended June 30, 2018, the Company estimated the fair value of the warrants granted to Eugene Seymour on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:

Expected life (year)	5
Expected volatility	53.56	%
Expected annual rate of quarterly dividends	0.00	%
Risk-free rate(s)	2.56

Series A Preferred stock

Schedule of fair value of Series A Preferred Stock

The fair value of the Series A Preferred Stock was the following for the dates indicated:

Date	Shares	Value
7/31/2017	129	$	8,242
8/31/2017	129		8,397
9/30/2017	129		8,588
10/31/2017	129		7,011
11/30/2017	129		6,313
12/31/2017	129		6,513
1/31/2018	129		5,552
2/28/2018	129		5,404
3/03/2018	1,340		60,725
3/31/2018	129		5,811
4/30/2018	129		5,215
5/31/2018	129		4,639
6/30/2018	129		3,696
	2,888	$	136,106

The fair value of all Series A preferred stock issued during the year ended June 30, 2019 was the following for the dates indicated:

Date	Shares	Value
7/11/2018	26,250	$	560,690
7/31/2018	129		2,795
8/31/2018	129		2,374
9/30/2018	129		2,598
10/31/2018	129		2,233
11/30/2018	129		1,883
12/31/2018	129		2,245
1/31/2019	129		1,203
2/28/2019	129		1,949
3/01/2019	1,340		24,340
3/31/2019	129		2,336
4/30/2019	129		1,636
5/31/2019	129		1,540
6/30/2019	129		1,696
	29,138	$	609,518